Upgrade to SI Premium - Free Trial

Neurogene (NGNE)

31.53 +0.74 (2.40%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/7/26)

Latest Headlines

Form 4/A Neurogene Inc. For: Jun 14 Filed by: Woods Keith June 16, 2026 5:32 PM - SEC Filing Form 4/A Neurogene Inc. For: Jan 16 Filed by: Woods Keith June 16, 2026 5:32 PM - SEC Filing Form 4/A Neurogene Inc. For: Jun 12 Filed by: Woods Keith June 16, 2026 5:32 PM - SEC Filing Form 3/A Neurogene Inc. For: Dec 18 Filed by: Woods Keith June 16, 2026 5:30 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Neurogene (NGNE) June 9, 2026 6:47 AM - StreetInsider Form 8-K Neurogene Inc. For: Jun 08 June 8, 2026 7:33 AM - SEC Filing Neurogene completes dosing in gene therapy trial for Rett syndrome June 8, 2026 7:31 AM - StreetInsider Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome June 8, 2026 7:30 AM - BizWire Form 8-K Neurogene Inc. For: Jun 03 June 4, 2026 4:41 PM - SEC Filing Rodman & Renshaw Starts Neurogene (NGNE) at Buy, PT $70 June 3, 2026 6:42 AM - StreetInsider Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 2, 2026 4:01 PM - BizWire Neurogene (NGNE) PT Raised to $65 at Craig-Hallum May 15, 2026 9:42 AM - StreetInsider Neurogene (NGNE) Misses Q1 EPS by 139c May 12, 2026 5:28 PM - StreetInsider Form 8-K Neurogene Inc. For: May 12 May 12, 2026 4:07 PM - SEC Filing Form 10-Q Neurogene Inc. For: Mar 31 May 12, 2026 4:05 PM - SEC Filing Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates May 12, 2026 4:05 PM - BizWire Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy May 12, 2026 6:00 AM - BizWire Form 4 Neurogene Inc. For: May 06 Filed by: Cvijic Christine Mikail May 8, 2026 11:51 AM - SEC Filing Form 4 Neurogene Inc. For: May 05 Filed by: Shafer Christina May 7, 2026 12:36 PM - SEC Filing Form 144 Neurogene Inc. Filed by: Cvijic Christine Mikail May 6, 2026 4:14 PM - SEC Filing Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 6, 2026 4:01 PM - BizWire Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy April 28, 2026 7:30 AM - BizWire Guggenheim Reiterates Buy Rating on Neurogene (NGNE) April 28, 2026 6:10 AM - StreetInsider Form 3 Neurogene Inc. For: Apr 20 Filed by: Shafer Christina April 20, 2026 6:27 PM - SEC Filing Form 8-K Neurogene Inc. For: Apr 20 April 20, 2026 7:33 AM - SEC Filing Neurogene names Christy Shafer as chief commercial officer April 20, 2026 7:30 AM - StreetInsider Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors April 20, 2026 7:30 AM - BizWire Form ARS Neurogene Inc. For: Dec 31 April 16, 2026 4:23 PM - SEC Filing Form DEFA14A Neurogene Inc. April 16, 2026 4:16 PM - SEC Filing Form DEF 14A Neurogene Inc. For: Jun 03 April 16, 2026 4:16 PM - SEC Filing Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 8, 2026 4:01 PM - BizWire Neurogene (NGNE) PT Lowered to $180 at Canaccord April 6, 2026 6:35 AM - StreetInsider Form 4 Neurogene Inc. For: Mar 26 Filed by: Cvijic Christine Mikail March 30, 2026 5:49 PM - SEC Filing Form 4 Neurogene Inc. For: Mar 26 Filed by: McMinn Rachel March 30, 2026 5:48 PM - SEC Filing Form 4 Neurogene Inc. For: Mar 26 Filed by: Jordan Julie March 30, 2026 5:48 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Neurogene (NGNE) March 26, 2026 6:48 AM - StreetInsider Form S-8 Neurogene Inc. March 24, 2026 4:18 PM - SEC Filing Form 10-K Neurogene Inc. For: Dec 31 March 24, 2026 4:05 PM - SEC Filing William Blair on Neurogene (NGNE): dosing update further de-risks NGN-401 profile March 24, 2026 10:50 AM - StreetInsider Leerink Partners stays Outperform on Neurogene (NGNE) following Q4 results; cites de-risked path March 24, 2026 10:28 AM - StreetInsider Form 8-K Neurogene Inc. For: Mar 24 March 24, 2026 7:32 AM - SEC Filing Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates March 24, 2026 7:30 AM - BizWire Full Article List